Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population

British Medical Journal

Volumn 312, Issue 7044, 1996, Pages 1443-1448

  Pharoah, P D P ^a,b   Hollingworth, W ^b  

^a FULBOURN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; STATIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0029942112     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.312.7044.1443     Document Type: Article

References (29)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian simvastatin survival study. Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, Isles C, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
3. British Medical Association, Royal Pharmaceutical Society of Great Britain, British national formulary. London: BMA and Pharmaceutical Press, 1995.
4. Martens LL, Rutten FF, Erkelens DW, Ascoop CA. Cost effectiveness of cholesterol-lowering therapy in the Netherlands. Simvastatin versus cholestyramine. Am J Med 1989;87:54-8S.
5. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-51.
6. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994;16:1052-62.
7. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032-8.
8. Davey Smith G, Pekkanen J. The Scandinavian simvastatin survival study. Lancet 1994;344:1766.
9. Grodos D, Tonglet R. The Scandinavian simvastatin survival study. Lancet 1994;344:1768.
10. Malik I, Anderson MH. Cost-efficacy of cholesterol lowering: implications of the Scandinavian simvastatin survival study. Eur Heart J 1995;16:463. (Abstract.)
11. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S). Lancet 1995;345:1274-5.
12. Rose G, Shipley M. Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study. BMJ 1986;293:306-7.
13. Martin MJ, Hulley SB, Browner WS, Kuller LH, Went worth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986;ii:933-6.
14. Shaper AG, Pocock SJ, Walker M, Phillips AN, Whitehead TP, MacFarlane PW. Risk factors for ischaemic heart disease: the prospective phase of the British regional heart study. J Epidemiol Community Health 1985;39:197-209.
15. Rose G, Hamilton PJ, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocar-dial ischaemia, risk factors and deaths from coronary heart disease. Lancet 1977;i:505-9.
16. Ulvenstam G, Bergstrand R, Johansson S, Vedin A, Wilhelmsson C, Wedel H, et al. Prognostic importance of cholesterol levels after myocardial infarction. Prev Med 1984;13:355-66.
17. Frost PH, Verter J, Miller D. Serum lipids and lipoproteins after myocardial infarction: association with cardiovascular mortality and experience in the aspirin myocardial infarction study. Am Heart J 1987;113:1356-64.
18. Suhonen O, Reunane A, Knekt P, Aromaa A. Risk factors for sudden and non-sudden coronary death. Acta Med Scand 1988;223:19-25.
19. Pekkanen J, Linn S, Heiss G, Suchindran CM, Lean A, Rifkind BM, et al. Ten year mortality for cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;32:1700-7.
20. Department of Health. Public health common data set. London: DoH, 1992.
21. White A, Nicolaas G, Foster K, Browne F, Carey S. Health survey for England 1991. London: HMSO, 1993.
22. Sawitz E, Showstack JA, Chow J, Schroeder SA. The use of in-hospital physician services for acute myocardial infarction. JAMA 1988;259:2419-22.
23. Sculpher MJ, Seed P, Henderson RA, Buxton MJ, Pocock SJ, Parker J, et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the randomised intervention treatment of angina (RITA) trial. Lancet 1992;344:927-30.
24. NHS Management Executive. Capital investment manual: business case guide. London: HMSO, 1994
25. Sheldon TA. Discounting in health care decision-making: time for a change? J Public Health Med 1992;14:250-6.
26. McKay MD, Conover WJ, Beckman RJ. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 1979;211:239-45.
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
28. Burr ML, Gilburt JF, Holliday RM, Elwood PC. Effect of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;ii:757-60.
29. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin J, Monjaud I, et al. Mediterranean alpha-linoleic-rich diet in the secondary prevention of coronary heart disease. Lancet 1994;344:1454-9.